Meanwhile, a multicentre, single-arm, phase I/II trial (immuno-MESODEC) is currently underway in which vaccination with WT1/DC is combined with conventional platinum/pemetrexed-based chemotherapy and with the anti-PD-L1 antibody Atezolizumab in 15 treatment-naïve patients with inoperable epithelioid mesothelioma [39]. This evidence concerns the gene WT1 and malignant epithelioid mesothelioma.